Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 13, Number 10—October 2007

Dispatch

Multidrug-Resistant Salmonella Typhimurium, Pacific Northwest, United States

Margaret A. Davis*Comments to Author , Thomas E. Besser*, Kaye Eckmann†, J. Kathryn MacDonald†, Donna Green†, Dale D. Hancock*, Katherine N.K. Baker*, Lorin D. Warnick‡, Yesim Soyer‡, Martin Wiedmann‡, and Douglas R. Call*
Author affiliations: *Washington State University, Pullman, Washington, USA; †Washington State Department of Health Public Health Laboratories, Shoreline, Washington, USA; ‡Cornell University, Ithaca, New York, USA;

Main Article

Table 1

Trends in resistance of bovine-origin Salmonella S. Typhimurium PFGE types TYP035 and TYP187*

Resistance characteristics† 2001 2002 2003 2004 2005 2006
TYP035
ASu 1 1 1
ACaz 1
AKSuT 1 1
AKSSuT 7 7 1 4 1 4
ACKSSuT 1 1
AKSSuTCaz 3
AKSxtSSuT 1
ACKSSuTCaz 2 2
ACKSxtSSuT 1
AKSuTCaz 1
AKSSuTCaz 1 1
ACKSSuTCaz 2 1
ACKSxtSSuTCaz 1 1 6 4
AGKSxtSSuTCaz





1
Total
8
10
5
17
12
8
TYP187
ACSSuTCaz 1
AKSSuTCaz 1 12
AKSuTCaz




1

Total 1 2 12

*PFGE, pulsed-field gel electrophoresis.
†A, ampicillin; Su, triple-sulfa; Caz, ceftazidime; K, kanamycin; T, tetracycline; S, streptomycin; C, chloramphenicol; Sxt, trimethoprim-sulfamethoxazole; G, gentamicin. In April 2005 nitrofurantoin, trimethoprim, and ciprofloxacin were dropped from the panel, and amoxicillin-clavulanic acid, nalidixic acid, and ceftazidime-clavulanic acid were added.

Main Article

TOP